Long-term outcomes of modern multidisciplinary management of sinonasal cancers: The M. D. Anderson experience

被引:5
|
作者
Bahig, Houda [1 ,2 ]
Ehab, Hanna Y. Y. [3 ]
Garden, Adam S. S. [1 ]
Ng, Sweet Ping [1 ,4 ]
Frank, Steven J. J. [1 ]
Nguyen, Theresa [1 ]
Gunn, Gary B. B. [1 ]
Rosenthal, David I. I. [1 ]
Fuller, Clifton D. D. [1 ]
Ferrarotto, Renata [5 ]
Bell, Diana [6 ]
Su, Shirley [3 ]
Phan, Jack [1 ]
机构
[1] Univ Texas MD Anderson Canc Ctr, Dept Radiat Oncol, 1515 Holcombe Blvd,Unit 0097, Houston, TX 77030 USA
[2] Ctr Hosp Univ Montreal, Dept Radiat Oncol, Montreal, PQ, Canada
[3] Univ Texas MD Anderson Canc Ctr, Dept Head & Neck Surg, Houston, TX 77030 USA
[4] Austin Hlth, Olivia Newton John Canc Ctr, Dept Radiat Oncol, Melbourne, Vic, Australia
[5] Univ Texas MD Anderson Canc Ctr, Dept Thorac Head & Neck Med Oncol, Houston, TX 77030 USA
[6] Univ Texas MD Anderson Canc Ctr, Dept Pathol, Houston, TX 77030 USA
关键词
conformal radiotherapy; head and neck cancer; IMRT; IMPT; intensity modulated radiation therapy; proton therapy; paranasal sinus cancer; radiation therapy; radiotherapy; sinonasal tumors; SNUC; SCC; VMAT; INTENSITY-MODULATED RADIOTHERAPY; PARANASAL SINUS CANCER; NASAL CAVITY; RADIATION-THERAPY; MAXILLARY SINUS; UNDIFFERENTIATED CARCINOMA; PROGNOSTIC-FACTORS; CLINICAL-OUTCOMES; PROTON THERAPY; PHOTON THERAPY;
D O I
10.1002/hed.27381
中图分类号
R76 [耳鼻咽喉科学];
学科分类号
100213 ;
摘要
PurposeTo report long-term outcomes of modern radiotherapy for sinonasal cancers. Methods and materialsA retrospective analysis of patients with sinonasal tumors treated with intensity-modulated radiotherapy or proton therapy. Multivariate analysis was used to determine predictive variables of progression free survival (PFS) and overall survival (OS). ResultsThree hundred and eleven patients were included, with median follow-up of 75 months. The most common histologies were squamous cell (42%), adenoid cystic (15%), and sinonasal undifferentiated carcinoma (15%). Induction chemotherapy was administered to 47% of patients; 68% had adjuvant radiotherapy. Ten-year local control, regional control, distant metastasis free survival, PFS, and overall survival rates were 73%, 88%, 47%, 32%, and 51%, respectively. Age, non-nasal cavity tumor site, T3-4 stage, neck dissection, and radiation dose were predictive of PFS, while age, non-nasal cavity tumor site, T3-4 stage, positive margins, neck dissection, and use of neoadjuvant chemotherapy were predictive of OS. There was a 13% rate of late grade >= 3 toxicities. ConclusionThis cohort of patients with sinonasal cancer treated with modern radiotherapy demonstrates favorable disease control rate and acceptable toxicity profile.
引用
收藏
页码:1692 / 1703
页数:12
相关论文
共 50 条
  • [31] Occult breast cancer (OBC), a retrospective analysis of clinico-pathological characteristics and long-term outcome: the University of Texas M. D. Anderson Cancer Center experience.
    Morandi, P
    Middleton, LP
    Mirza, NQ
    Vlastos, G
    Kau, SW
    Perkins, GH
    Kuerer, HM
    Gonzalez-Angulo, AM
    Hortobagyi, GN
    Cristofanilli, M
    BREAST CANCER RESEARCH AND TREATMENT, 2004, 88 : S165 - S165
  • [32] Management and Long-Term Outcomes of Sinonasal Undifferentiated Carcinoma: Twenty-Year Experience at a Single Institution
    Liao, J. J.
    Jewell, P.
    Parvathaneni, U.
    Laramore, G.
    Polissar, N.
    Wong, W.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2014, 90 : S544 - S545
  • [33] Glioblastoma: Clinical Presentation, Multidisciplinary Management, and Long-Term Outcomes
    Sipos, David
    Raposa, Bence L.
    Freihat, Omar
    Simon, Mihaly
    Mekis, Nejc
    Cornacchione, Patrizia
    Kovacs, Arpad
    CANCERS, 2025, 17 (01)
  • [34] Cytoreductive nephrectomy in the elderly patient: The M. D. Anderson cancer center experience - Editorial comment
    DeWolf, William C.
    JOURNAL OF UROLOGY, 2007, 177 (03): : 860 - 861
  • [35] Treatment with Tyrosine Kinase Inhibitors for Patients with Differentiated Thyroid Cancer: the M. D. Anderson Experience
    Cabanillas, Maria E.
    Waguespack, Steven G.
    Bronstein, Yulia
    Williams, Michelle D.
    Feng, Lei
    Hernandez, Mike
    Lopez, Adriana
    Sherman, Steven I.
    Busaidy, Naifa L.
    JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM, 2010, 95 (06): : 2588 - 2595
  • [36] INDUCTION TREATMENT FOR DIFFUSE INTRINSIC PONTINE GLIOMA, EXPERIENCE OF M. D. ANDERSON CANCER CENTER
    Wolff, Johannes
    Rytting, Michael
    Tribhawa, Vats
    PEDIATRIC BLOOD & CANCER, 2011, 57 (05) : 877 - 877
  • [37] Survival outcomes for men with mediastinal germ-cell tumors: The University of Texas M. D. Anderson Cancer Center experience
    Rodney, Alan J.
    Tannir, Nizar M.
    Siefker-Radtke, Arlene O.
    Liu, Ping
    Walsh, Garrett L.
    Millikan, Randall E.
    Swisher, Stephen G.
    Tu, Shi-Ming
    Pagliaro, Lance C.
    UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2012, 30 (06) : 879 - 885
  • [38] Phase I clinical trial outcomes in 93 patients with brain metastases: The M. D. Anderson Cancer Center experience.
    Iskander, N. G.
    Tsimberidou, A. M.
    Letourneau, K.
    Wen, S.
    Wheler, J. J.
    Hong, D. S.
    Naing, A.
    Kurzrock, R.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [39] Long-term outcome of patients with complete eradication of cytologically proven axillary node metastases after primary chemotherapy: The University of Texas M. D. Anderson Cancer Center experience.
    Hennessy, BTJ
    Kuerer, H
    Sahin, A
    Buzdar, AU
    Kau, SW
    Singletary, SE
    Hortobagyi, GN
    Valero, V
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 28S - 28S
  • [40] Long-term follow-up of patients with newly diagnosed acute myeloid leukemia treated at the University of Texas M. D. Anderson Cancer Center
    Estey, E
    deLima, M
    Strom, S
    Pierce, S
    Freireich, EJ
    Keating, MJ
    CANCER, 1997, 80 (11) : 2176 - 2180